The Valley Desk

NCT05228015 · Interventional trial

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Overall registry status Terminated

Phase 1

Conditions Epithelioid Hemangioendothelioma (EHE), Malignant Pleural Mesothelioma (MPM), NF2 Deficiency, NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, Solid Tumor, Solid Tumors, Adult, YAP1 or TAZ Gene Fusions

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov